相似文献
1
Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.
Int J Mol Sci. 2020 Mar 31;21(7):2435. doi: 10.3390/ijms21072435.
2
Pluripotent Stem Cells in Clinical Setting-New Developments and Overview of Current Status.
Stem Cells. 2022 Sep 26;40(9):791-801. doi: 10.1093/stmcls/sxac040.
3
Recent Trends in Research with Human Pluripotent Stem Cells: Impact of Research and Use of Cell Lines in Experimental Research and Clinical Trials.
Stem Cell Reports. 2018 Aug 14;11(2):485-496. doi: 10.1016/j.stemcr.2018.06.012. Epub 2018 Jul 19.
4
Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Biotechnol Adv. 2013 Dec;31(8):1600-23. doi: 10.1016/j.biotechadv.2013.08.009. Epub 2013 Aug 17.
5
The safety of human pluripotent stem cells in clinical treatment.
Ann Med. 2015;47(5):370-80. doi: 10.3109/07853890.2015.1051579. Epub 2015 Jul 6.
6
The Manufacture of Xeno- and Feeder-Free Clinical-Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy.
Int J Mol Sci. 2022 Oct 18;23(20):12500. doi: 10.3390/ijms232012500.
7
Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
Stem Cell Rev Rep. 2017 Dec;13(6):757-773. doi: 10.1007/s12015-017-9766-9.
8
Haematopoietic developmental potential of human pluripotent stem cell lines.
Folia Biol (Praha). 2014;60 Suppl 1:90-4.
9
Human embryonic and induced pluripotent stem cells in clinical trials.
Br Med Bull. 2015;116:19-27. doi: 10.1093/bmb/ldv045. Epub 2015 Nov 17.
10
History and current status of clinical studies using human pluripotent stem cells.
Stem Cell Reports. 2023 Aug 8;18(8):1592-1598. doi: 10.1016/j.stemcr.2023.03.005. Epub 2023 Apr 6.
引用本文的文献
1
Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.
Pharmacol Rev. 2025 Jun 26;77(5):100077. doi: 10.1016/j.pharmr.2025.100077.
2
Airway epithelial stem cell renewal and differentiation: overcoming challenging steps towards clinical-grade tissue engineering.
Stem Cell Res Ther. 2025 Jul 6;16(1):351. doi: 10.1186/s13287-025-04478-0.
3
A comprehensive analysis of induced pluripotent stem cell (iPSC) production and applications.
Front Cell Dev Biol. 2025 May 8;13:1593207. doi: 10.3389/fcell.2025.1593207. eCollection 2025.
4
Methods for Pluripotent Stem Cell Characterization: A Narrative Review.
Cureus. 2025 Jan 13;17(1):e77362. doi: 10.7759/cureus.77362. eCollection 2025 Jan.
5
Quality and Regulatory Requirements for the Manufacture of Master Cell Banks of Clinical Grade iPSCs: The EU and USA Perspectives.
Stem Cell Rev Rep. 2025 Apr;21(3):645-679. doi: 10.1007/s12015-024-10838-9. Epub 2025 Jan 17.
6
Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice.
Nat Commun. 2024 Nov 1;15(1):9433. doi: 10.1038/s41467-024-53613-7.
7
Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies.
Int J Surg. 2024 Oct 1;110(10):6432-6455. doi: 10.1097/JS9.0000000000001892.
8
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".
Int J Mol Sci. 2023 Dec 10;24(24):17320. doi: 10.3390/ijms242417320.
9
New characterization and safety evaluation of human limbal stem cells used in clinical application: fidelity of mitotic process and mitotic spindle morphologies.
Stem Cell Res Ther. 2023 Dec 13;14(1):368. doi: 10.1186/s13287-023-03586-z.
10
iPSC-based approach for human hair follicle regeneration.
Front Cell Dev Biol. 2023 May 30;11:1149050. doi: 10.3389/fcell.2023.1149050. eCollection 2023.
本文引用的文献
1
Quantification of the morphological characteristics of hESC colonies.
Sci Rep. 2019 Nov 26;9(1):17569. doi: 10.1038/s41598-019-53719-9.
2
Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts.
EBioMedicine. 2019 Apr;42:443-457. doi: 10.1016/j.ebiom.2019.03.011. Epub 2019 Mar 26.
3
GMP-compatible manufacturing of three iPS cell lines from human peripheral blood.
Stem Cell Res. 2019 Mar;35:101394. doi: 10.1016/j.scr.2019.101394. Epub 2019 Feb 11.
4
Direct application of induced pluripotent stem cells is feasible and can be safe.
Theranostics. 2019 Jan 1;9(1):290-310. doi: 10.7150/thno.28671. eCollection 2019.
5
Next generation sequencing-based gene panel tests for the management of solid tumors.
Cancer Sci. 2019 Jan;110(1):6-15. doi: 10.1111/cas.13837. Epub 2018 Nov 27.
6
Quality control guidelines for clinical-grade human induced pluripotent stem cell lines.
Regen Med. 2018 Oct;13(7):859-866. doi: 10.2217/rme-2018-0095. Epub 2018 Sep 12.
7
Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers.
Front Med (Lausanne). 2018 Mar 15;5:69. doi: 10.3389/fmed.2018.00069. eCollection 2018.
8
Concise Review: Assessing the Genome Integrity of Human Induced Pluripotent Stem Cells: What Quality Control Metrics?
Stem Cells. 2018 Jun;36(6):814-821. doi: 10.1002/stem.2797. Epub 2018 Feb 18.
9
Monitoring cell line identity in collections of human induced pluripotent stem cells.
Stem Cell Res. 2018 Apr;28:66-70. doi: 10.1016/j.scr.2018.01.030. Epub 2018 Jan 31.
10
Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration.
Regen Med. 2018 Mar;13(2):123-128. doi: 10.2217/rme-2017-0130. Epub 2017 Dec 6.
Zotero 插件